Skip to main content
BEIJING CENTERGATE TECHNOLOGIES (HOLDING) CO., LTD logo

BEIJING CENTERGATE TECHNOLOGIES (HOLDING) CO., LTD — Investor Relations & Filings

Ticker · 000931 ISIN · CNE000001030 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,999 across all filing types
Latest filing 2024-10-09 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000931

About BEIJING CENTERGATE TECHNOLOGIES (HOLDING) CO., LTD

https://www.centek.com.cn

Beijing Centergate Technologies (Holding) Co., Ltd. focuses on the research, development, production, and distribution of medical and healthcare products. The company’s core operations involve the manufacturing of chemical pharmaceuticals, traditional Chinese medicines, and health supplements. Its product portfolio addresses various therapeutic areas, including cardiovascular health, digestive system treatments, and anti-infective therapies. Additionally, the company provides healthcare services and develops medical devices. Through its specialized subsidiaries, it maintains integrated research and manufacturing capabilities aimed at providing clinical solutions and health management products. The organization emphasizes technological advancement and quality control across its supply chain to meet diverse patient needs and healthcare standards.

Recent filings

Filing Released Lang Actions
《房地产抵押估价报告》【世联估字 BJ2024D（2）090015 号】
Audit Report / Information Classification · 95% confidence The document is a detailed real estate appraisal report for a property located in Beijing, including valuation methods, assumptions, legal and physical property descriptions, and a comprehensive valuation summary. It is prepared by a registered real estate appraisal firm for the purpose of determining mortgage loan value. The document contains substantive valuation data, legal references, and detailed property information. It is not an announcement or a brief summary but a full appraisal report. This type of document does not fit into typical financial report categories like Annual Report or Earnings Release, nor is it a regulatory filing or management announcement. Given the nature of the document as a professional valuation report, it aligns best with the category of Audit Report / Information (AR), which includes applied accounting principles and valuation reports related to assets, excluding full annual reports. Therefore, the correct classification is AR with high confidence.
2024-10-09 Chinese
《房地产抵押估价报告》【英华房报字[2024]1079号】
Regulatory Filings
2024-10-09 Chinese
关于公司和山东华素为山东中关村向日照银行和威海市商业银行申请18,000万元项目贷款提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's and its subsidiary's provision of guarantees for a project loan application. It details the loan amount, the collateral, the guarantee terms, and related financial data of the subsidiary. The document is titled as an "announcement" and is relatively short (3,671 characters). It does not contain comprehensive financial statements or detailed financial performance analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it focuses on a specific financing-related event, namely the provision of guarantees for a loan. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is CAP with high confidence.
2024-10-09 Chinese
《房地产抵押估价报告》【北京首佳（2024）估字第FC20240102568Z号】
Regulatory Filings
2024-10-09 Chinese
关于下属公司北京华素取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (713 characters) about a subsidiary company obtaining an invention patent certificate issued by the National Intellectual Property Office. It includes details about the patent and states that it will not have a significant impact on recent operations but will enhance the company's intellectual property protection. There is no financial data, no mention of financial results, no regulatory filings, or management changes. It is an announcement of a patent acquisition, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-10-09 Chinese
《资产评估报告》【山东鲁业资评（2024）第00045号】
Audit Report / Information Classification · 95% confidence The document is an asset evaluation report for patents owned by 山东华素制药有限公司 (Shandong Huashu Pharmaceutical Co., Ltd.). It includes detailed descriptions of the evaluation purpose, scope, methods (notably the income approach), legal and regulatory bases, and the evaluation conclusion with a valuation date of June 30, 2024. The document is lengthy (15,000 characters) and contains substantive financial and valuation data, not merely an announcement or summary. It is not an annual or interim financial report, nor a regulatory filing or announcement. It is a formal asset evaluation report, which aligns with the category of Audit Report / Information (AR), as it is a standalone report on asset valuation and related accounting principles, not a full annual report or earnings release. Therefore, the appropriate classification is AR with high confidence.
2024-10-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.